Recent studies indicated the prognostic role of AXL in NSCLC suggesting a new additional tool to customized therapy of EGFR treated patients12 and also to the stratification of operable early stage lung adenocarcinoma patients that might benefit from new targeted adjuvant therapy13. Here, EGFR is linked to non-small cell lung carcinoma.